Yinhua Gouteng decoction alleviates tic disorder symptoms by modulating neuro-inflammation in a rat model.
A rat study shows a Chinese herbal drink cut tics and brain swelling, but offers no ready ABA tool.
01Research in Context
What this study did
Scientists gave rats a drug that causes tics. The rats then drank a Chinese herbal mix called Yinhua Gouteng decoction for several days.
The team watched the rats’ movements and later checked brain samples for swelling markers.
What they found
The herbal drink lowered both tic behaviors and brain swelling signals in the rats.
Results pointed to positive effects, but the work was done only with animals.
How this fits with other research
Kim et al. (2023) and Canitano et al. (2007) looked at real children, not rats. They found tics in about one in five kids with autism.
Carter et al. (2011) also studied children and showed that tics often travel with anxiety and ADHD.
These human studies describe the problem; Hu et al. (2026) tests a drug fix in animals. The pieces sit side-by-side: human description meets animal intervention.
Why it matters
The rat data hint that calming brain swelling might ease tics. For now, ABA teams should keep using behavior plans, not herbs. Stay alert for future human trials that may add medical options to your toolkit.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Keep your standard behavior plan; note any clients who also report tics for team medical check-ups.
02At a glance
03Original abstract
Tic disorders (TDs) are childhood-onset neurodevelopmental disorders characterized by complex neurochemical dysregulation, and inflammation plays a critical role in TD pathogenesis. Yinhua Gouteng Decoction (YHGTD), a traditional Chinese medicinal formula, has demonstrated clinical efficacy in TD management. However, the specific pharmacological mechanisms underlying its effects remain unclear. In this study, we investigated the neuroprotective and anti-inflammatory effects of YHGTD in a 3,3′-iminodipropionitrile (IDPN)-induced TD rat model. A rat model of IDPN-induced was established. Behavioral assessments, striatal histopathology, and quantification of striatal dopamine (DA) levels and dopamine receptor (DR) expression were measured to assess the effects of YHGTD on tic symptoms and dopaminergic function. Microglial activation was examined by immunofluorescence staining, while IL-1β, TNF-α, and IL-6 in serum, striatum, and colon were quantified using ELISA or qPCR. In addition, 16S rRNA sequencing was used to analyze alterations in the gut microbiota composition. Western blotting was performed to assess TLR4/MyD88/NF-κB pathway activation in the striatum and colon. YHGTD significantly improved motor and stereotypical behaviors in TD rats, decreased spontaneous activity, total travel distance, prolonged rest time, and normalized movement trajectories. It attenuated striatal neuropathology, elevated DA levels, and downregulated the expression of DRD1 and DRD2. YHGTD also suppressed microglial activation and reduced the levels of IL-1β, TNF-α, and IL-6 in the striatum, serum, and colon. Furthermore, YHGTD restored gut microbial homeostasis and reduced the abundance of proinflammatory bacterial taxa. Finally, we found that YHGTD downregulated the TLR4/MyD88/NF-κB signaling pathway in both the striatum and colon. YHGTD alleviated TD symptoms through neuroprotective and anti-inflammatory mechanisms, accompanied by alterations in the microbiota composition, supporting its potential as a therapeutic option for TD.
Frontiers in Immunology, 2026 · doi:10.3389/fimmu.2025.1680975